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Abstract
Background: Most women with a clinical presentation consistent with ovarian cancer have benign conditions. Therefore
methods to distinguish women with ovarian cancer from those with benign conditions would be beneficial. We describe the
development and preliminary evaluation of a serum-based multivariate assay for ovarian cancer. This hypothesis-driven
study examined whether an informative pattern could be detected in stage I disease that persists through later stages.
Methodology/Principal Findings: Sera, collected under uniform protocols from multiple institutions, representing 176
cases and 187 controls from women presenting for surgery were examined using high-throughput, multiplexed
immunoassays. All stages and common subtypes of epithelial ovarian cancer, and the most common benign ovarian
conditions were represented. A panel of 104 antigens, 44 autoimmune and 56 infectious disease markers were assayed and
informative combinations identified. Using a training set of 91 stage I data sets, representing 61 individual samples, and an
equivalent number of controls, an 11-analyte profile, composed of CA-125, CA 19-9, EGF-R, C-reactive protein, myoglobin,
apolipoprotein A1, apolipoprotein CIII, MIP-1a, IL-6, IL-18 and tenascin C was identified and appears informative for all
stages and common subtypes of ovarian cancer. Using a testing set of 245 samples, approximately twice the size of the
model building set, the classifier had 91.3% sensitivity and 88.5% specificity. While these preliminary results are promising,
further refinement and extensive validation of the classifier in a clinical trial is necessary to determine if the test has clinical
value.
Conclusions/Significance: We describe a blood-based assay using 11 analytes that can distinguish women with ovarian
cancer from those with benign conditions. Preliminary evaluation of the classifier suggests it has the potential to offer
approximately 90% sensitivity and 90% specificity. While promising, the performance needs to be assessed in a blinded
clinical validation study.
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Introduction
Ovarian cancer is the deadliest gynecological cancer in the
United States [1]. In 2008, an estimated 21,650 new cases of
ovarian cancer will be detected. Early diagnosis is associated with a
92% 5-year survival rate, yet only 19% of ovarian cancers are
detected early [1,2]. The majority of cases detected are advanced
stage disease where 5-year survival rates for women with regional
malignancy and distant disease are 71% and 30% respectively. As
a result, more than 15,000 women die from ovarian cancer in the
US each year [1].
The early symptoms of ovarian cancer, which include pelvic and
abdominal pain, urinary urgency and frequency, abdominal
bloating, and difficulty eating are non-specific, and typical of many
non-cancerous and benign conditions [3]. Therefore, diagnosis does
not typically occur until the development of either a significant
amount of abdominal fluid, or a pelvic mass, detected by physical
examination or with radiologic evaluation [4]. A recent report has
suggested that a unique combination of symptoms, if fully
documented for each patient, may be more informative than
previously recognized, although the findings remain to be validated
[5]. Many reports indicate that the most commonly used imaging
techniques – transvaginal sonography (TVS), positron-emission
tomography (PET), magnetic resonance imaging (MRI), radio-
immunoscintigraphy and computed tomography (CT) lack sufficient
specificity to distinguish between benign and malignant ovarian
disease [6]. Some recent studies have suggested that ultrasound
alone, or in combination with other prognostic variables may be
significantly more informative in the hands of a specialized ovarian
ultrasound expert [7,8], however, many patients do not have access
to the skills of such specialists. Moreover, clear diagnosis usually
necessitates, at minimum, surgical intervention in the form of
laparotomy or laparoscopy. Therefore, an accurate, informative, yet
non-invasive, test would be of clinical value.
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4599There are no FDA-approved biomarkers for the diagnosis of
ovarian cancer, or for the triage of women suspected of having
ovarian cancer. Despite its widespread use, cancer antigen 125
(CA-125) is only FDA-approved for monitoring recurrence and
therapeutic response [9–11]. In studies of women with known or
suspected ovarian cancer, the reported sensitivities of CA-125 in
detecting stage I and II cancers range widely from 29–75% and
67–100%, respectively. However, CA-125 is elevated in a wide
variety of normal, benign and malignant conditions [12–14] and
86% of women presenting with abnormal CA-125 tests resolve in
3–6 months [15]. Many approaches have been taken to improve
the predictive value of CA-125 through serial measurements
[16,17] or in combination with additional markers [18–21].
However, a simple and clinically practical ovarian cancer-
screening tool remains elusive.
A recent study [22] described a panel of six markers – CA-125,
prolactin, leptin, macrophage inhibitory factor (MIF), osteopontin
and insulin-like growth factor II (IGF-II) that when combined had
very high sensitivity (95.3%) and specificity (99.4%). The test is
intended as a screen on high-risk women, however, the final
performance characteristics were not assessed on high-risk women
and included samples also used to build models which may have
resulted in over-estimation of the classifier’s performance.
Moreover, inclusion and exclusion criteria for participants were
not clearly defined, and the cancer and control samples were
collected under different clinical settings, which can lead to bias in
the sample set. Prolactin and IGF-II were each reported to be
individually more informative than CA-125, in this study, but this
is inconsistent with reports on other independent sample sets
[23,24]. In another study, Moore and colleagues utilized logistic
regression to find marker combinations capable of differentiating
between benign and malignant conditions in women with pelvic
masses [25]. By combining HE-4 and CA-125, 76.4% sensitivity
and 95% specificity was achieved. While promising, only 67 of the
233 samples were from individuals with ovarian cancer and only
15 of those from women with stage I and II cancers. In addition,
reported performance was based on cross-validation results which
lacked an independent holdout set of samples.
Ovarian cancer is a collection of diverse entities with more than
30 subtypes of malignancies, each with a distinctive histology,
pathology and clinical behavior [26]. The diversity and low
incidence of ovarian cancer hampers the search for biomarkers. In
a separate, post-hoc analysis, of a subset of the samples used in the
present study, we were unable to identify a single marker capable
by itself of accurately predicting the presence of ovarian cancer
[24]. In this present study, we describe the development and
preliminary evaluation of a multi-analyte profile that can classify




All but 20 samples were from the tissue-banking repository of
the National Cancer Institute-funded Gynecologic Oncology
Group (GOG; Columbus, OH; Table 1; Table S2). Written
consent was obtained by the GOG for all participants and the
GOG Institutional Review Board (IRB) approved the use of the
samples in our study. These samples were collected from multiple
sites, under protocols approved by the GOG IRB. Eligible patients
were women scheduled for surgery with suspicion of having a
gynecological cancer or scheduled for prophylactic surgery
because of increased ovarian cancer risk (1st or 2nd degree
relative with the disease). All samples, including those categorized
as normals, post-surgery, were collected prior to any diagnostic or
therapeutic intervention. Serum aliquots forwarded to Correlogic
Systems, Inc.H (Rockville, MD) had been de-identified and
encoded with a unique GOG identifier. Each sample was
accompanied by a complete clinicopathology report, patient age
and race, and a de-identified code denoting the collection site.
Pathology was reviewed and confirmed by GOG pathologists to
ensure consistency. Samples were selected from the GOG
collection to balance patient age distribution, date of serum
collection, and representation of cases and controls across
collection sites. The remaining sera consisted of 20 samples from
individuals with benign conditions from a Correlogic prospective
collection, which uses a similar serum collection protocol. Written
consent was obtained from all participants. Correlogic’s ‘‘prospec-
tive’’ samples are being collected under IRB approval to support
the development of a clinical test for ovarian cancer. The study
population is women presenting with symptoms of ovarian cancer
and scheduled for surgery. As such, disease status is confirmed by
Table 1. Demographics of study subjects.
1{
Stage







61 (34.7) 31 (17.6) 67 (38.1) 12 (6.8) 5 (2.8) 176 (100) 32 (17.1) 140 (74.9) 15 (8.0) 187 (100)
Median Age (range) 53.0 (29–80) 56.0 (39–85) 57.0 (42–87) 66.5 (28–78) 71.0 (52–80) 56.0 (28–87) 45.5 (29–72) 52.0 (15–88) 54.0 (27–89) 50 (15–89)
Mean Age (SD) 55.8 (11.0) 57.6 (10.3) 59.5 (11.8) 62.8 (14.7) 68.5 (11.8) 58.3 (11.6) 47.9 (9.5) 54.3 (14.4) 55.8 (16.7) 53.4 (14.1)
Serous 12 18 31 10 3 74 (42.0) - - - -
Mucinous 6 3 6 1 0 16 (9.1) - - - -
Clear cell 17 0 9 0 1 27 (15.3) - - - -
Endometrioid 22 8 13 1 1 45 (25.6) - - - -
Mixed 4 2 8 0 0 14 (8.0) - - - -
1Two low malignant potential samples not tabulated.
{All samples were sourced from a single GOG study with the exception of 20 benign samples which were sourced from a Correlogic prospective collection as described
in ‘‘Methods – Sample Cohort’’. Only GOG samples are shown in this table.
*Other cancers consisted of 4 endometrial cancers, 7 cervical cancers, 3 colon cancers and 1 uterine cancer.
{The most common benign sample types were cystadenoma, endometrioma/endometriosis, cyst, Brenner tumor and adenofibroma.
#Staging based on FIGO, International Federation of Gynecology and Obstetrics. Stage X, staging not available. OvCa, ovarian cancer.
doi:10.1371/journal.pone.0004599.t001
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from the prospective collection in a manner to avoid introducing
any bias into the remaining collection and as such were not
deliberately selected to represent any particular population. The
study was approved by the Western IRB (Olympia, WA) and by
the IRB of each participating site.
Serum Processing, Storage, Handling and Shipment
Blood samples (5–20 ml) were collected into red top glass
Vacutainer tubes (Becton-Dickinson, NJ), clotted for 30–180 min-
utes at 4uC, and then centrifuged at 3,500 g for 10 minutes at 4uC.
Serum was decanted into cryotubes, and stored promptly at
280uC. Aliquots from storage were shipped to Correlogic on dry
ice and stored immediately at 280uC. Frozen samples were
warmed gently by hand until almost thawed, completed on ice,
vortexed, aliquoted in 150 ul volumes and refrozen at 280uC.
Finally, samples were shipped on dry ice to Rules-Based Medicine,
Inc. (RBM; Austin, TX). An accompanying document provided a
coded sample identification number and a specific order of
analysis. The RBM analytical site was completely blinded to all
sample details including disease status.
Multiplex Immunoassays
The multiplexed immunoassays are described elsewhere [24].
Briefly, two rounds of multiplexed immunoassays were conducted
at RBM in their Luminex-based CLIA-certified laboratory.
Analytes were quantified by reference to 8-point calibration
curves and machine performance was verified using three quality
control (QC) samples for each analyte. QC samples were
distributed relatively evenly across the dynamic range of the assay
at low, medium and high levels and generally had coefficients of
variance below 15%. Calibration standards and QC samples were
in a complex plasma-based matrix to match the sample
background and were analyzed in duplicate. In round one, a
total of 204 analytes representing 104 antigens, 44 autoimmune
and 56 infectious disease molecules were measured in 147
epithelial ovarian cancer samples (40 stage I, 23 stage II, 67 stage
III, 12 stage IV, five unstaged) and 149 control samples (104
benign conditions, 29 normal healthy, 14 other cancers and two
low malignant potential) using proprietary multiplexed immuno-
assays (Table S1). A second round of analysis was performed 86
days after the first analytical round, on the 104 antigens, using a
second serum aliquot that had been subjected to an identical
freeze/thaw history as the samples used in round one. Due to
sample volume restrictions, 27 samples were not reanalyzed in
round two. Thus, in round two, 132 ovarian cancer samples (30
stage I, 21 stage II, 65 stage III, 11 stage IV and five unstaged) and
135 controls (94 benign conditions, 28 normal healthy, 13 other
cancers) were reanalyzed. In addition, a further 69 samples, not
included in round one, were analyzed (21 stage I, eight stage II, 36
benign, three normal healthy and one colon cancer). For both
rounds of analysis, the order of analysis was established to avoid
any sequential bias due to disease presence or absence, subtype or
stage of disease, patient age, or age of the serum sample.
Generally, samples alternated between cases and controls.
Data Handling
Since sera were analyzed at a previously optimized dilution, any
sample exceeding the maximum concentration of the calibration
curve was arbitrarily assigned the concentration of the highest
standard, whereas those assayed below the minimum concentra-
tion of the calibration curve were assigned the value 0.0. A single
assay (IL-1a) that showed no variation in expression across all
samples was considered invariant/uninformative and removed
from the extracted data set. The remaining data were then scaled
by the biweight scale; a robust and efficient scaling mechanism
that accounts for the variance within each of the individual assays
[27]. A single scale for each assay was determined in a population-
weighted manner. Any assay yielding a scale factor of zero was
removed from the data set. The resulting data were then exported
into individual files where each file represented the results of all
qualified assays for a single sample.
Modeling – ‘‘Out-of-Bag’’ Error Estimation and Bootstrap
Validation
To minimize sample set bias and to aid in the assessment of
intermediate models, we employed one-third ‘‘out-of-bag’’ (OOB)
error estimation and an external 100-fold bootstrap validation
with 10% holdout bootstraps. These bootstrap estimates allowed
us to assess the potential value of many models using only the
training data. In this way we were able to maintain the
independence of the hold-out testing set of samples. Only after a
specific classifier had been locked into a traceable document
management system (DMS) were the hold-out testing set of data
used to test performance of the selected model.
Modeling – Proof-of-Principle Classifier
Initially, modeling was performed with data generated in round
one (Figure 1) using a modification of Breiman’s Random Forest
code [28]. The method was improved by enabling batch
automation, adding an external layer of bootstrapping, providing
greater control over run parameters, and customizing output. The
resulting trees were saved and a proprietary routine was used to
score samples and output sample information, probability scores,
and classification result. Forty stage I ovarian cancer and 40
control samples were used for model building. The controls were
selected to ensure that the modeling set represented the same
proportions of normal, benign and other cancer conditions as the
whole control set, however, within each of those categories,
samples were selected randomly. Modeling was optimized by
varying both the tree counts (50, 100, 500 and 1000) in a forest,
and the number of biomarkers (5, 10, 15, 20, 25, 30, 35, 40, 45,
50) explored at each branching point, resulting in 40 models. From
these models, the 20 most informative analytes were identified
using the variable importance value. In the second step, a series of
models were built that were restricted to the most important
analyte (1-analyte model), the two most important analytes (2-
analyte model) and so on to a 20-analyte model, a total of 20
models. The OOB and external bootstrap errors, and their
standard deviations, were tabulated for each of these models.
From these results it was determined that a minimum of seven
analytes were required to achieve the most accurate classification.
A final, single, model was then built on these seven analytes and
deposited into the DMS as a ‘‘locked’’ model.
Modeling – Final Classifier
The final modeling incorporated all stage I cancer data from
rounds one and two, including the duplicates – a total of 91 stage I
data sets, representing 61 unique samples and an identical number
of controls, matched as before, and balanced in the same round
one to round two ratio (Figure 1). Only these data sets (i.e. the
training set) were used in model building and selection. The
pattern analysis was performed using a unique, patent-pending
algorithm, Knowledge Discovery Engine-VS (KDE-VS
TM). KDE-
VS utilizes a group of voting structures similar to decision trees
with a unique method of building and defining the cut-off values
within each voting structure, using not only the measured value of
Ovarian Cancer Assay
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doi:10.1371/journal.pone.0004599.g001
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with that measurement, derived from the historical QC measure-
ments for each analyte. The user can vary the fractional value of
the error estimate incorporated into a classifier during modeling.
The result is a robust classifier that can withstand significant
perturbation of experimentally determined point values of analyte
concentrations. During model building, each terminal node on the
voting structure is assigned to a given state – either ovarian cancer
or non-ovarian cancer. To score an unknown, our software
extracts the values for the analytes of interest to determine which
node the sample falls in.
Two different modeling runs, with fractional value of error
tolerances of 1.0 and 3.0, were performed using data for the 104
antigen assays. The 20 most robust analytes were determined for
each run and these were then assembled into an exhaustive set of
7-marker models. However, all models were required to contain
an invariant core of the three most robust and informative
analytes, namely CA-125, C-reactive protein and EGF-R, which
reduced the search space to 2380 combinations. For both levels of
error tolerance we identified the ten most sensitive and ten most
specific models – giving a total of 40 models. The frequency of use
of both individual analytes and various analyte combinations
across all 40 models, led to the identification of 11 analytes that
together appeared robust and informative. Finally, a single model
was built on these 11 analytes and locked in the DMS. Only after
locking the model were the remaining data, not used in training,
scored to test the model (Figure 1).
Data Analysis
Confidence intervals were calculated using the Newcombe
method [29].
Results
Preliminary Evaluation of the Proof-of-Principle Classifier
The first set of data, generated on 147 ovarian cancer and 149
non-ovarian cancer control samples was used to explore the
potential of using a high throughput multiplex immunoassay
platform as a discovery tool. We hypothesized that a classification
pattern for stage I ovarian cancer would persist through all later
stage diseases, so only stage I cancer samples were used for model
development. This approach also balanced the average age of case
and control patients, removing age-related bias during modeling
(Table 1). Through several rounds of enrichment for the most
informative biomarkers, driven by the assessment of bootstrap
errors for the model development sample set, a 7-analyte model
evolved, consisting of CA-125, EGF-R, C-reactive protein,
apolipoproteins CIII and A1, IL-18 and tenascin C. This stage I
specific profile was locked into the DMS. Only after the model was
locked into the DMS was the data for the testing samples (those
not used in modeling) accessed and scored by the model to give the
results described below (Figure 1).
Since all stage I data generated in the first round of assays had
been used in modeling, there were no independent data to test
stage I sensitivity. However, the 100-fold bootstrap estimate of
stage I sensitivity was 87% (Table 2). The bootstrap estimate for
specificity, based on the controls used in model development was
82.3%. The classifier was then evaluated using round one testing
samples, a set of independent samples not used in any aspect of
model development. The classifier had 95.3% sensitivity and
70.6% specificity. Performance for benign samples was lower
(67.1%) than other controls. There was no single subtype of cancer
that scored significantly different from the others and when broken
down by stage, the sensitivity varied little (94.0–100%), supporting
the hypothesis that a stage I pattern could persist through all stages
of disease. Following the second round of assays, all round two
data were scored on this locked model. The samples common to
round one showed a reproducible performance with 97.1%
sensitivity (95% CI, 91.0–99.2%) and 74.5% specificity (95% CI,
64.7–82.4%). The additional 69 samples, not previously analyzed,
provided a second testing set and yielded 85.7% sensitivity for
stage I, 100% sensitivity for stage II and 67.5% specificity.
Preliminary Evaluation of the Final Classifier
The proof-of-principle classifier confirmed our hypothesis that
using only stage I data for both model development and
assessment we could identify an informative pattern that may
exist and persists through later stages of cancer. Therefore, we
sought to develop the stage I model further using all stage I
samples available. The same modeling strategy was repeated with
two important modifications. First, a different, proprietary
algorithm was implemented, and second, all stage I samples
analyzed across both rounds one and two were used to increase the
size of the model development data set (Figure 1). The modeling
strategy went through several iterative steps to enrich for the most
informative biomarkers, based on an assessment only of stage I
training data before culminating in a near-exhaustive search of
biomarker combinations that generated 2380 models. Forty
models were selected based on their bootstrap sensitivity and
specificity on the stage I sample set. By comparing the biomarker
combinations in these top 40 models (Table 3), and considering
the balance they showed in bootstrap accuracy, sensitivity,
specificity, and standard deviations, a final set of 11 informative
biomarkers were identified. Certain analyte combinations were
common in many models, and there were clearly ‘‘substitution
patterns’’ where a different analyte or combination of analytes
could yield equivalent models. The 11 biomarkers – CA-125, C-
reactive protein, EGF-R, CA 19-9, apolipoproteins A1 and CIII,
myoglobin, MIP-1a, IL-6, IL-18 and tenascin C – were assembled
into a final model using the KDE-VS algorithm and locked into
the DMS as the final model (Figure 1).
As a preliminary test of the classifier’s performance, all data not
used in model development were scored, yielding 91.3% sensitivity
and 88.5% specificity (Table 4, Figure 1). Notably, stage II
sensitivity was 83.9% and performance on the benign samples
improved to 90.4%. Additional stage I samples were not available,
at that time, for testing of this performance. However, the
bootstrap estimate of sensitivity for the training set was 83.4% for
stage I disease and 84.2% (612.5%) specificity (Table 4). As a
separate exercise, all duplicate data from round two not used in
model development were scored. As anticipated from the previous
results, the performance was similar with 96.1% sensitivity (95%
CI, 89.7–98.7%) and 88.1% specificity (95% CI, 80.8–93.0%) with
benign samples scoring 87.0% (95% CI, 76.2–93.5%). To provide
a frame of reference, we compared the model performance to that
of a clinical decision based on CA-125 expression levels. Since the
cut-off value of 35 IU/ml is already established, the complete data
set was used to assess the predictive value of CA-125. With this
cut-off value, CA-125 gave 94.9% sensitivity and 58.6% specificity
(Table 5). For stage I samples alone, the sensitivity dropped to
88.5%.
We implemented two methods to estimate the importance of the
different analytes to the overall classifier. First, we assessed model
performance when all but one analyte was held constant in the
data files, with the value of the chosen analyte randomized. This
was repeated sequentially for each analyte. The relative value of
each analyte was then ranked by determining which analyte
caused classification performance to decline the most when
Ovarian Cancer Assay
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group together. Specifically, CA-125 was the most important
biomarker, followed a group consisting of C-reactive protein, CA
19-9 and EGF-R, followed by MIP-1a, followed by myoglobin,
apolipoprotein CIII, apolipoprotein A1, IL-18 and IL-6 and finally
tenascin C. As a second method of estimating analyte importance,
we analyzed the branching points of the voting structures. Across
all branching points of the voting structures, CA-125 was involved
the most frequently (15.8%) followed by CA 19-9 (12.1%),
myoglobin (11.1%), C-reactive protein (10.8%) and EGF-R
(9.9%). CA-125 was utilized in 80% of the top-level branching
points, representing the first major sample partitioning, followed
by C-reactive protein (11.2%), EGF-R (5.0%) and CA19-9 (1.8%).
At the second tier, CA19-9 was used most frequently (20.3%)
followed by EGF-R (18.8%), CA-125 (11.4%), myoglobin (9.8%),
tenascin C (8.0%), IL-18 (7.2%), and apolipoprotein A1 (6.9%).
Table 2. Preliminary Performance Evaluation of the 7-Analyte Proof-of-Principle Classifier.
State Stage or subtype Testing – Round One Testing – Round Two
Correct/Total (%) 95% CI Correct/Total (%) 95% CI
Ovarian Cancer Stage I -/40 (87.0*) N/A 18/21 (85.7) 62.6–96.2
Stage II 22/23 (95.7) 76.0–99.8 8/8 (100) 59.8–100
Stage III 63/67 (94.0) 84.7–98.1 - -
Stage IV 12/12 (100) 69.9–100 - -
Stage X 5/5 (100) 46.3–100 - -
Combined 102/107
# (95.3) 88.9–98.3
# 26/29 (89.7) -
Non-Ovarian Cancer Benign 49/73 (67.1) 55.0–77.4 24/36 (66.7) 48.9–80.9
Normal 19/24 (79.2) 57.3–92.1 3/3 (100) 31.0–100
Other Cancers 9/12 (75.0) 42.8–93.3 0/1 (0) 0–94.5
Combined 77/109 (70.6) 61.0–78.8 27/40 (67.5) 50.8–80.9
*The 40 round one stage I samples were used in model development, therefore results for stage I samples are estimates based on 100-fold bootstrap validation.
#stage I values are not included in these calculations, all other samples listed in the table were not used in developing the proof-of-principle model. Correct/Total, the
number of samples correctly classified / the total number of samples for each sample type; 95% CI, 95% confidence interval for the result; N/A, not applicable. Stage X,
staging not available.
doi:10.1371/journal.pone.0004599.t002
Table 3. Biomarkers in the Ten Most Specific and Sensitive 7-Marker Models Using a Noise Parameter of 1.0*.
Biomarkers Model Number
1234567891 01 11 21 31 41 51 61 71 81 92 0
CA-125
# xxxxxxxxxx x x x xxxxxxx
CRP
# xxxxxxxxxx x x x xxxxxxx
EGF-R
# xxxxxxxxxx x x x xxxxxxx
CA 19-9 xxxxxxxxx x x x xxxxxxx
SAP xxx
Apo A1 xx
IL-6 xx x x x x
Myoglobin x xxx xxxxxxx
MIP-1a xxxx xxxx x x x x
vWF xx x
Leptin xx
Apo CIII xx x
GH xx x xx x
IL-18 xx x x x x x x
MPO xx
VCAM-1 xx x
*A comparable list was generated for a noise parameter of 3.0; x, biomarker used in a given model.
#All models were required to contain an invariant core of the three most robust and informative analytes, namely CA-125, C-reactive protein and EGF-R. CA, cancer
antigen; CRP, C-reactive protein; EGF-R, soluble epidermal growth factor receptor; SAP, serum amyloid P; Apo, apolipoprotein; MIP-1a, macrophage inhibitory protein




PLoS ONE | www.plosone.org 6 February 2009 | Volume 4 | Issue 2 | e4599The acute phase markers MIP-1a and IL-6 were seen only 6.2%
and 1.3% respectively at this level.
Discussion
In this study we identified a classification pattern for ovarian
cancer in the serum proteome of patients with stage I disease,
which remains evident through later stage disease. Sera from
patients with pathologist-confirmed conditions – either with or
without epithelial ovarian cancer – were profiled using a bead-
based multi-analyte profiling approach. The analytes covered a
broad range of biological structures and functions, including
cancer antigens, hormones, clotting factors, tissue modeling
factors, lipoprotein constituents, proteases and protease inhibitors,
markers of cardiovascular risk, growth factors, cytokine/chemo-
kines, soluble forms of cell-signaling receptors, and inflammatory
and acute phase reactants as well as markers for autoimmunity
and infection (Table S1). Two independent analyses of samples
were performed 86 days apart. There were several reagent lot and
batch changes during this period, providing a real world challenge
to the robustness of the underlying assays and the model.
Four major components were critical to the success of this
study. First, it was essential to identify a highly consistent, well-
documented and clinically representative sample set of con-
firmed cases and controls. For ovarian cancer, confirmation can
only come from pathologic examination of surgically excised
tissue. We selected serum samples from well-characterized
collections from women already scheduled for surgery. The
substantial majority of controls in this population had pathology-
confirmed benign conditions, which based on univariate analysis,
should pose a greater challenge for classification than sera from
non-symptomatic women (Figure 2; [24]). Second, we utilized a
panel of fully qualified, high throughput, immunoassays that
measure a wide diversity of molecules including autoimmune
and infectious disease markers, and a wide range of well
characterized serum proteins, including those previously impli-
cated in ovarian cancer. Third, we used a novel multivariate
modeling approach to identify a robust pattern of molecules
informative for ovarian cancer. The proprietary algorithm
Table 4. Preliminary Evaluation of the Final 11-analyte Classifier.
Ovarian Cancer Number of samples
# Correct classification % Sensitivity 95% CI
Stage I 61 - 83.4% (612.4%)*
Stage II 31 26 83.9 65.5–93.9
Stage III 67 62 92.5 82.7–97.2
Stage IV 12 12 100.0 69.8–100
Unstaged 5 5 100.0 46.3–100
Combined
" 115 105 91.3 84.2–95.5
Non-Ovarian Cancer Number of samples
# Correct classification % Specificity 95% CI
Benign 73 66 90.4 80.7–95.7
Prospective Benign
{ 20 17 85.0 61.1–96.0
Normal 24 21 87.5 66.5–96.7
Other Cancer 13 11 84.6 53.7–97.3
Combined 130 115 88.5 81.4–93.2
#The final model was used to score all round one data, excluding those used in model development, and all additional samples unique to round two, which were not
used in model development.
*the performance for the stage I samples is an estimate based on the 100-fold bootstrap results.
{these benign samples are from Correlogic’s prospective collection, collected under an IDE to support the development of a clinical test for ovarian cancer. The study
population is women scheduled for surgery presenting with symptoms of ovarian cancer. As such, disease status is pathology confirmed following surgery.
"stage I values are not included in these calculations. 95% CI, 95% confidence interval for the result.
doi:10.1371/journal.pone.0004599.t004
Table 5. Comparison of the Classification Performance of CA-125, the Proof-of-Principle and the Final Classifier.
Method Sensitivity 95% CI Specificity 95% CI
All Samples* CA-125.35 IU/ml 94.9% 90.5–97.6 58.6% 51.9–65.6
Stage I only
# CA-125.35 IU/ml 88.5% 77.8–95.3 58.6% 51.9–65.6
Proof-of-principle 7-analyte classifier
{ 94.1% 88.4–97.2 69.8% 61.7–76.9
Final 11-analyte classifier
" 91.3% 84.2–95.5 88.5% 81.4–93.2
*Since the cut-off value of 35 IU/ml is already established, the complete data set, excluding duplicates was used to assess the predictive value of CA-125.
#sensitivity for all stage I samples only, excluding duplicates.
{sensitivity and specificity determined using the 136 ovarian cancer and 149 non-ovarian cancer samples, excluding duplicates, not used in development of the 7-
anlayte classifier.
"sensitivity and specificity determined using the 115 ovarian cancer and 130 non-ovarian cancer samples, excluding duplicates, not used in development of the 11-
anlayte classifier. 95% CI, 95% confidence interval for result.
doi:10.1371/journal.pone.0004599.t005
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PLoS ONE | www.plosone.org 7 February 2009 | Volume 4 | Issue 2 | e4599Figure 2. Serum level distributions for the analytes used in the final 11-analyte classifier. For each analyte, the box-whisker plots show:
the lowest observation, lower quartile, median value, upper quartile, and highest observation. All analyses, including duplicates are shown. CA-125 –
one ovarian cancer, 11 benign and five normal samples below lowest calibration value; CA 19-9 – 14 ovarian cancer, 18 benign, nine normal and four
other cancer samples below lowest calibration value; C-reactive protein – 93 ovarian cancer, 21 benign, two normal and two other cancer samples
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Random Forest and other classification algorithms by building
robust decision boundaries into its voting structures, which
incorporates real-world experimental variability into the data
being modeled. Finally there was a clear separation between
samples used to develop and identify a single informative model,
and the samples used to evaluate that models performance.
Our study focused on the analysis of early stage disease with
.50% of the cancer sample set representing stages I and II disease
(Table 1). Consistent with the literature, the average patient age at
diagnosis correlated with the stage of disease at diagnosis (Table 1;
[22]). The subtype distribution was representative of the US
population, with a larger proportion of serous (42%) and
endometrioid (26%) carcinoma (Table 1). The control samples
were predominantly from individuals with common benign
ovarian conditions (75%), as well as other gynecological and
non-gynecological cancers (8%), and a small number of non-
diseased samples (17%), consistent with the need for a clinical test
for symptomatic women (Table 1).
Our rationale to focus on early stage disease was two-fold.
Firstly, early stage ovarian cancer is considered curable, but in
many cases symptoms are subtle and hard to detect. If there is an
informative pattern in stage I disease, it would be useful to identify
for later validation. Secondly, we sought to minimize the impact of
CA-125 on the development of any potential classification pattern.
It is widely accepted that CA-125 is more elevated in late stage
disease than early stage disease, and is the most strongly correlated
single biomarker for ovarian cancer at any stage [24], although it
lacks specificity. By examining stage I disease, where CA-125 may
be less dominant, we hypothesized that other informative
proteomic combinations might be discovered and that these
would persist through later disease stages. Our results support
these assumptions for the sample set studied. Indeed, in later work
(unpublished) in which we built classification models using later
disease stages for the model development set, we did identify
patterns strongly predictive of ovarian cancer. However, the
patterns were dominated by CA-125 and had poor performance
when evaluated on early stage disease samples.
All stage I samples were devoted to model development to
maximize the training sample set size. Therefore, a weakness of
this study is the lack of samples to test independently the
performance on stage I disease. Bootstrap estimates have proven
to be good indicators in our model building to date. In the proof-
of-principle classifier, bootstrap estimates predicted the 7-bio-
marker model would have an accuracy of 87% on stage I samples.
This was supported when independent round two, stage I samples
were scored by the model with an 85.7% accuracy. For the final
modeling run that generated the 11-analyte model, the bootstrap
estimate predicted a stage I sensitivity of 83.4%. While our
strategy involved several steps and training data were used
repetitively to refine the set of the most informative assays it is
critical to appreciate that only the model development set,
composed of the stage I data and an equal number of non-
ovarian cancer data, were used repetitively. The other data were
never used until a final model was locked into the DMS for final
testing. Therefore the performance characteristics we observed for
all non-stage I cancer and non-ovarian cancer samples not used in
model building are independent results.
To assess the impact of sample bias on our results, we examined
three potential sources of concern. Age is a risk factor for ovarian
cancer, and could therefore introduce bias caused by age or
menopausal differences between the cases and controls. We
addressed this in several ways. Firstly, we used a strategy in which
the average age of cases and controls were very similar in the
model development set. Secondly, in a separate modeling analysis
we reorganized the model development set into two groups
divided by age (#50 years versus $61 years), irrespective of
disease status. Interestingly, infectious disease markers were the
predominant predictors of age, perhaps reflecting different
vaccination or exposure histories. A similar type of analysis was
undertaken to address the different length of storage of individual
sera in the 280uC freezer. This did not give statistically significant
classification. Finally, we attempted to build classifiers for samples
that were completely randomized regardless of disease status and
again, no statistical significant multivariate classifiers could be
generated.
Only after this modeling had been completed, the performance
characteristics of individual markers were determined on the
sample set used in round one of this study [24]. Interestingly, the
combination of markers in the final model is not the combination
that would be selected from the best individual analytes. Indeed
most of the selected markers provide little classification value for
cancer status when considered alone as individual markers
(Figure 2; [24]) with only CA-125 and C-reactive protein having
appreciable classification potential. The markers in the 11-analyte
classifier reflect a variety of biological functions. However, two
cancer antigens, CA-125 and CA 19-9, along with EGF-R, a
truncated signaling receptor associated with cell growth and
differentiation, and the inflammatory marker C-reactive protein
are involved in the majority of initial decisions in the voting
structure and primarily drive the performance of the classifier. The
remaining markers are cytokines (IL-18, IL-6 and MIP-1a),
metabolic markers (apolipoproteins A1 and CIII), myoglobin (an
oxygen carrier) and tenascin C (an extracellular matrix protein).
While it is difficult to predict the particular biological roles of the
markers that contribute to the ovarian cancer pathology, they are
all implicated in multiple pathways associated with tumor growth
and metastasis. In this context it is interesting to note that the
combination of both CA-125 and CA 19-9 provide complimentary
information for non-mucinous (CA-125 elevated) and mucinous
(CA 19-9 elevated) cancers [30]. One other immediate observation
is the implication of three proteins (C-reactive protein, IL-6, MIP-
1a) commonly associated with an acute phase response. While it
has been proposed that up to 23% of ovarian cancers have a
chronic inflammatory component [31], it is notable that the
relative importance of IL-6 and MIP-1a to other analytes in the
11-analyte classifier is low, reflected both by the calculated
importance value, and the absence of IL-6 and MIP-1a in the 7-
analyte classifier. Since both IL-6 and MIP-1a are multifunctional
proteins, it is difficult to know if their biological roles are purely
inflammatory, or more complex.
The selection of myoglobin in the final 11-analyte classifier was
not intuitive. It is primarily considered a marker of muscle damage
and the underlying biological role that myoglobin plays in ovarian
cancer is unclear. Indeed, myoglobin levels do not appear to differ
significantly between the ovarian cancer and control samples [24]
above highest calibration value; IL-6 – 82 ovarian cancer, 161 benign, 28 normal and 14 other cancer samples below lowest calibration level; MIP-1a –
50 ovarian cancer, 53 benign, 10 normal and four other cancer samples below lowest calibration level; tenascin C – two ovarian cancer and one
benign sample above highest calibration level. OvCa, ovarian cancer; Ca, cancer; Apo, apolipoprotein; CA-125, cancer antigen 125; CA 19-9, cancer
antigen 19-9; EGF-R, epidermal growth factor receptor (soluble form); IL, interleukin; MIP-1a, macrophage inflammatory protein 1 alpha.
doi:10.1371/journal.pone.0004599.g002
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the classifier. Analysis of the voting structures indicates that
myoglobin, as well as tenascin C, are often used as a terminal
decision point forming the final decisions on whether a sample is
classified as a case or control. This may reflect a role in
normalizing the relative expression levels for the other analytes.
In our method of model development it is not possible to fix a
pre-desired sensitivity or specificity for a classifier. Therefore, we
have not presented an ROC curve. In an ROC curve built upon a
single variable (such as CA-125), the cut-off values on the curve
reflect the analyte concentrations measured. In this instance,
changing cut-offs for a given sensitivity and specificity is very
practical. In a multivariate index, there is a large dimensional
reduction interpreting multiple analyte concentrations into a single
value which now represents an index value. In the case of a
regression equation of the form ax+by, the same index value can
be achieved by many different combinations of x and y. As the
number of parameters in the expression increase, so do the
combinations. A similar effect occurs in our voting structures
where many different combinations of voting structures can lead to
a similar overall vote. Moreover, the way the voting structures are
built depends upon a set of decision rules, which guide their
evolution. These rules are intimately tied into how a branch point
in the voting structure is defined, and therefore changing the ROC
cut-off after a model is built is not valid. Any cut-off that does not
reflect the rules used to create the models during model
development will not be robust. However, the shape and AUC
of the ROC are useful envisioning and comparing the overall
accuracy of different multivariate indexes. An ROC curve
generated on the final 11-analyte model, using only samples not
used in model development, to avoid over-fitting, yielded an area
underneath the curve (AUC) value of 0.953, significantly better
than CA-125 alone [24].
Women who are suspected of having ovarian cancer require a
thorough clinical assessment to determine their risk for ovarian
cancer. Many women present with benign pelvic masses that are
treated effectively by surgical recision, under the care of an
obstetrician–gynecologist or general surgeon. When a pelvic mass
proves to be a malignant neoplasm, formal staging and thorough
surgical resection is required to achieve an optimal likelihood of
cure [32]. Therefore it is clinically useful to have a test that will
lead women with a high likelihood of having ovarian cancer into
the care of a gynecologic oncologist [33] while taking care not to
over-refer benign conditions. Guidelines to help assess and triage
patients have been addressed by the American College of
Obstetricians and Gynecologists (ACOG) and the Society of
Gynecologic Oncologists (SGO), however strict adherence to these
guidelines is often incomplete. A blood-based test that could
improve this triage would be of benefit [32]. The 11-analyte
classification pattern described in this paper has characteristics
consistent with this use, but requires a statistically significant
clinical validation on a validated, custom multiplex, to verify its
performance.
There are a number of limitations to our study. Firstly, the
performance of the classifier can only be considered preliminary and
is likely over-optimistic because of the nature of the testing set. The
testing samples were sourced from the same collection, and analyzed
at the same time as those used in model building (training).
Therefore, the performance on a truly independent set (i.e. from
different sources and analyzed at a different time point) is likely to be
lower. Validation on a totally independent set must be conducted
and thisforms thebasis of our ongoing studies.Secondly,ourstudyis
specifically focused on epithelial ovarian cancers. We intentionally
excluded non-epithelial ovarian cancer subjects because they are
rare, and it would be difficult to identify sufficient numbers for a
statistically sound study. Thirdly, we limited the number of low
malignant potential (LMP) tumors because there are differences of
opinion on how to classify LMP tumors. In order to establish a clear
hypothesis we focused on the classification of pathology proven
epithelial ovarian cancers from pathology proven ovarian benign
conditions. As such, the performance of the test in our preliminary
evaluation can not be generalized to a clinical population, which
would require an independent validation study.
Supporting Information
Table S1 Assays Performed on Samples. The antigen, autoim-
mune and infectious disease panels consisted of the following
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Found at: doi:10.1371/journal.pone.0004599.s001 (0.04 MB
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Table S2 Sources of Specimens by Collection Site.
Found at: doi:10.1371/journal.pone.0004599.s002 (0.08 MB
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